RxDoctor Payments Data

Ilan Bazak, DPM

Podiatrist · Los Angeles, CANPI 1932153970

Payments from drug & device makers

$4,220in general payments, 2019–2025

Across 77 payments — averaging $54.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • IBSA Pharma Inc.$750
  • Paratek Pharmaceuticals, Inc.$702
  • Amgen$431
  • Cardiovascular Systems Inc.$337
  • Smith+Nephew$265
  • Melinta Therapeutics, LLC$260
  • plus $1K from 10 others

What the payments were for

  • Consulting fees$75018%
  • Travel & lodging$80%
  • Food & beverage$3,44382%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,220 in reported general payments places this provider in the 80th percentile of 721 podiatrist providers in California.

See all podiatrist providers in California

Medicare billing

Part B allowed, 2024
$360,163
Medicare patients
753
Services billed
4,377

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tavaborole870$524,686
Diclofenac Sodium254$147,718
JubliaEfinaconazole121$92,166
Oxiconazole Nitrate163$77,537
Naproxen-Esomeprazole MagNaproxen/Esomeprazole Mag47$39,262
Diflorasone Diacetate76$30,578
MeloxicamMeloxicam, Submicronized27$23,518
Diclofenac Epolamine13$8,068
Chlorzoxazone12$7,704
Econazole Nitrate46$3,784
Lidocaine34$2,896
Clotrimazole33$795
CiclopiroxCiclopirox Olamine38$743
Triamcinolone Acetonide30$364
Ciclopirox12$317

Paid to pharmacies, not to this prescriber.

Other podiatrist in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →